Sales data specialists Cegedim to buy rivals Dendrite

pharmafile | March 2, 2007 | News story | Sales and Marketing |  Cegedim 

French specialist pharmaceutical database and software company Cegedim is to buy its US-based rivals Dendrite for $751 million.

Dendrite's board of directors has unanimously approved the acquisition and recommends that Dendrite's shareholders vote in favour of the deal.

The merger will create a major new force in pharmaceutical customer relations management (CRM) and salesforce management, a huge industry built around the pharma industry's tens of thousands of sales reps.

Advertisement

Jean-Claude Labrune, founder and chief executive of Cegedim said: "We are very excited to join forces with Dendrite's talented team to create a truly global business with increased international reach, a broader scope of product offerings and the strength to invest in the development of innovative technologies. As a combined organisation, we can achieve an even higher quality of service and will be better able to serve our clients in our competitive global marketplace."

Cegedim has a strong base in Europe, while Dendrite has a sizeable presence in the US and Asia Pacific markets. The companies say the combined group will be able to address the global needs of its customers and provide a unique suite of integrated, value-added products.

The combined company is expected to have estimated annual revenues of $1.1 billion and operate in more than 75 countries throughout Europe, the Americas and Asia Pacific.

Related Content

Changing business models top pharma concerns

The changing face of pharma business models is the main thing keeping US executives awake …

Blog footer

Digital Pharma: Social media an ‘enigma’ for pharma

The vast majority of pharma companies now use social media in one form or another, …

New clients for Cegedim Dendrite

Cegedim Dendrite, a leading provider of CRM software and healthcare data to the pharma industry, …

The Gateway to Local Adoption Series

Latest content